Argenx's Vyvgart Hytrulo Achieves Phase III Success in Autoimmune Myositis, Opening Blockbuster Market Beyond Neurology
On August 17, 2026, Dutch immunology innovator argenx announced positive topline results from its landmark Phase III ALKIVIA clinical trial evaluating subcutaneous Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with autoimmune myositis.
Autoimmune myositis is a chronic, rare inflammatory disease characterized by progressive muscle weakness and muscle destruction. There are currently very limited treatment options, and for some subtypes, no approved therapies exist. Efgartigimod is a first-in-class human IgG1 antibody fragment designed to bind to the neonatal Fc receptor (FcRn), which triggers the rapid degradation of circulating pathogenic IgG autoantibodies. Vyvgart and Vyvgart Hytrulo are already approved for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). This positive Phase III readout represents a major clinical milestone, paving the way for regulatory submissions and opening a multi-billion dollar market in rheumatology.
Clinical Data and Key Findings
The ALKIVIA trial evaluated the subcutaneous formulation of efgartigimod over 52 weeks in a cohort of patients with autoimmune myositis:
- Primary Endpoint Met: In the combined population of patients with immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM), treatment with Vyvgart Hytrulo achieved a highly statistically significant and clinically meaningful 15.4-point greater improvement in mean Total Improvement Score (TIS) compared to placebo at Week 52.
- Breakthrough in IMNM: The trial is the first-ever Phase III study to show statistically significant improvements in patients with immune-mediated necrotizing myopathy (IMNM), a severe, debilitating subtype of myositis that has historically had no approved treatment options.
- Rapid and Sustained Efficacy: The therapy demonstrated a rapid onset of clinical benefit that was sustained through the 52-week treatment period.
- Safety and Tolerability: The safety and tolerability profile of Vyvgart Hytrulo in the ALKIVIA trial was consistent with previously reported clinical studies, showing no new safety signals.
Argenx plans to present the full dataset at an upcoming medical meeting and intends to submit a Biologics License Application (BLA) to the FDA and other global regulatory agencies to expand Vyvgart Hytrulo's label into autoimmune myositis.